anyone else notice survodutide kicking in around week 89
Update, and the title has the headline: anyone else notice survodutide kicking in around week 89. Read the phase 2 hepatic paper properly and the endpoint definitions were more interesting than the headline response rate. The escalation schedules in the published protocols are slow and deliberate, and the…
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
The endpoint vocabulary, because you cannot read this literature without it.
Resolution of steatohepatitis without worsening of fibrosis and improvement in fibrosis without worsening of steatohepatitis are the two standard composite endpoints, both scored on biopsy by pathologists against a defined system. Liver fat fraction is an imaging surrogate that correlates imperfectly with histology.
A trial can move the surrogate substantially and the histological endpoint modestly. Both results are real; they answer different questions. Anybody quoting a response rate here should say which endpoint it refers to, and most summaries do not.
The endpoint vocabulary, because you cannot read this literature without it.
Adding the standing caveat — unapproved compound, research material is not for human use.
not approved anywhere, and the boards forget that constantly
MASH endpoints are histological, which is a much harder bar
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.